Patents by Inventor Robert Sikes

Robert Sikes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INDIRECT THREE-DIMENSIONAL CO-CULTURE OF DORMANT TUMOR CELLS AND USES THEREOF
    Publication number: 20220356452
    Abstract: The present invention relates to an indirect three-dimensional co-culture. The indirect co-culture may comprise bone marrow niche cells, tumor cells and a culture medium. The bone marrow niche cells and the tumor cells may be incubated in the culture medium without direct contact between the bone marrow niche cells and the tumor cells. The tumor cells may be dormant or reactivated. Also provided are a method for preparing the indirect co-culture and a method for screening for an agent capable of inhibiting reactivation of dormant tumor cells or promoting dormancy of proliferating tumor cells.
    Type: Application
    Filed: September 30, 2020
    Publication date: November 10, 2022
    Applicant: University of Delaware
    Inventors: April Kloxin, Lina Pradhan, Robert Sikes, Kenneth van Golen, DeVonte Moore
  • Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
    Patent number: 8450374
    Abstract: Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: May 28, 2013
    Assignee: University of Delaware
    Inventors: John Tze-tzun Koh, Paula Lynn McGinley, Hongmu Pan, Robert Sikes
  • Pan-Antagonists For The Androgen Receptor And Androgen Receptor Mutants Associated With Anti-Androgen Withdrawal
    Publication number: 20100331418
    Abstract: Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor.
    Type: Application
    Filed: June 29, 2010
    Publication date: December 30, 2010
    Inventors: John Tze-tzun KOH, Paula Lynn McGinley, Hongmu Pan, Robert Sikes